Relay Therapeutics, Inc. · NASDAQ:RLAY
Relay Therapeutics — Merger or Acquisition (April 2021)
14 slides from Relay Therapeutics's merger presentation, Apr 16, 2021
Slide 1: Conference Call April 2021
Conference Call April 2021 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, includin
Slide 3: Augmenting the Dynamo Platform Through the Acquisition of ZebiAI
Augmenting the Dynamo™ Platform Through the Acquisition of ZebiAI Extending Relay Tx’s Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines Experimentation Computation for the Dynamo™ platform and the drug discovery process Efficiency Effectiveness
Slide 4: 2021 Is a Year of Delivering on Catalysts
2021 Is a Year of Delivering on Catalysts 2016 2017-20 Built out the experienced team of 170 FTEs and an integrated platform Created and advanced 2 programs into clinical trials with a robust pre-clinical pipeline Entered partnership with Genentech for RLY-1971 Expanded approach from oncology to als
Slide 5: Relay Tx – Leader in Integrating Leading Edge Technologies
Relay Tx – Leader in Integrating Leading Edge Technologies Dynamo™️ Platform Protein NMR Cryo-EM Micro Electron Diffraction HDX-MS Output from Anton II & GPUs Long Time-scale MD Large System Simulation Lattice Simulation EXPERIMENTATION X-Ray Crystallography Virtual Screens Swimming Simulations FEP
Slide 6: We Have Validated Our Approach and Built Significant Advantage
Relay Tx – We Have Validated Our Approach and Built Significant Advantage Precision Medicine Clinical Programs Dynamic Structures Conformationally-Informed Screening Structure-Guided Pharmacology Molecular Dynamic Simulations Digitally-Encoded Libraries Machine Learning and Physics-Based Models Targ
Slide 7: ZebiAI – Novel Platform Based on a Big Data Approach
ZebiAI – Novel Platform Based on a Big Data Approach 101001110010010010010010001001010010010010010011010100011100101100010110001000001001001001010 111001001001001001000100101001001001001001101010001110010110001011000100000100100100101010100 10010010010010001001010010010010010011010100011100101100010
Slide 8: ZebiAI – ML Driven DEL Screening Capability
ZebiAI – ML Driven DEL Screening Capability Data Next Generation DEL Screening ML Models Generating Predictive Hits More Efficient Hit Finding and Lead Optimization Experimentation Computation Experimentation Data Data Data Increase efficiency and effectiveness of hit finding and lead generation Enh
Slide 9: ZebiAI – Validated Approach
ZebiAl — Validated Approach RELAY Journal of Medicinal Chemistry ubsacsorgiime == chine Learning on DNA-Encoded Libraries: A New Paradigm for Hit Finding Kevin McCloskey," Eric A. Sigel,’ Steven Kearnes, Ling Xue, Xia Tian, Dennis Moccia, Diana Gikunju, Sana Bazzaz, Betty Chan, Matthew A. Clark, Joh
Slide 10: What Does ZebiAI Bring to Relay Tx?
What Does ZebiAI Bring to Relay Tx? Key ZebiAI Attributes Experienced Team Large Datasets Validated ML-DEL Approach Complementary Vision Source: McCloskey et al., J. Med. Chem. Industry Leading Collaborations (Strategic Agreement with Leading DEL Provider, Collaboration with Google Accelerated Scien
Slide 11: ZebiAI Builds on Relay Tx's Strengths to Accelerate Our Capabilities
Relay Tx – ZebiAI Builds on Relay Tx’s Strengths to Accelerate Our Capabilities Precision Medicine Clinical Programs Dynamic Structures Conformationally-Informed Screening Structure-Guided Pharmacology Molecular Dynamic Simulations Digitally-Encoded Libraries Machine Learning and Physics-Based Model
Slide 12: Relay Tx – Aggregator of Emerging Technologies
Relay Tx – Aggregator of Emerging Technologies Dynamo™️ Platform Protein NMR Cryo-EM Micro Electron Diffraction HDX-MS Output from Anton II & GPUs Long Time-scale MD Large System Simulation Lattice Simulation EXPERIMENTATION X-Ray Crystallography Virtual Screens Swimming Simulations FEP Simulation C
Slide 13: What To Expect From Relay Tx
What To Expect From Relay Tx Nearer-term milestones Medium-/longer-term drivers 5 additional ongoing pre-clinical programs in precision oncology and genetic diseases Future opportunities in other TAs e.g., immunology, neuroscience $678M Cash & cash equivalents as of the end of Q4 2020 (not including
Slide 14: Slide 14
Relay Therapeutics — Merger or Acquisition (April 2021) on 6ix